Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (8057L)
23 Avril 2018 - 2:10PM
UK Regulatory
TIDMHCM
RNS Number : 8057L
Hutchison China Meditech Limited
23 April 2018
Grant of Share Options under Share Option Scheme
London: Monday, April 23, 2018: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) announces that on April 20, 2018, it
granted share options under the Share Option Scheme conditionally
adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015
HCML Share Option Scheme").
Chi-Med granted 762,690 share options under its 2015 HCML Share
Option Scheme to certain employees to subscribe for Ordinary Shares
subject to the acceptance of the grantees. Details of such share
options granted prescribed are as follows:
Date of grant : April 20, 2018
Exercise price of share : GBP46.45 per Ordinary Share
options granted
Number of share options : 762,690 (each share option
granted shall entitle the holder
thereof to subscribe for
one Ordinary Share)
Closing market price : GBP46.45 per Ordinary Share
of Ordinary Shares on
the date of grant
Validity period of the : From April 20, 2018 to April
share options 19, 2028
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance
& Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHPGUCUCUPRGPW
(END) Dow Jones Newswires
April 23, 2018 08:10 ET (12:10 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024